Products & Services · Total revenues
XGEVA — Total revenues
Amgen XGEVA — Total revenues decreased by 95.2% to $411M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 95.0%, from $8.15B to $411M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong market adoption and effective commercialization of the therapy, while a decrease may signal increased competition from biosimilars or a decline in the product's clinical lifecycle.
Detailed definition
This metric represents the total gross sales generated by the XGEVA product line, a therapeutic agent used for the preve...
Peer comparison
Comparable to revenue metrics for specific oncology or specialty pharmaceutical product lines at peer biotechnology firms.
Metric ID:
amgn_segment_xgeva_total_revenuesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $488M | $6.71B | $517M | $6.85B | $545M | $6.24B | $502M | $6.59B | $533M | $6.65B | $495M | $6.84B | $484M | $6.11B | $536M | $6.99B | $530M | $6.9B | $519M | $8.2B | $527M | $7.45B | $561M | $8.39B | $562M | $8.5B | $541M | $9.09B | $561M | $8.15B | $566M | $9.18B | $532M | $9.56B | $539M | $9.87B | $447M | $8.62B | $411M |
| QoQ Change | — | -92.5% | >999% | -92.3% | >999% | -92.0% | >999% | -92.0% | >999% | -91.9% | >999% | -92.6% | >999% | -92.9% | >999% | -91.2% | >999% | -92.4% | >999% | -92.5% | >999% | -93.6% | >999% | -92.5% | >999% | -93.3% | >999% | -93.6% | >999% | -93.8% | >999% | -93.1% | >999% | -94.2% | >999% | -94.4% | >999% | -95.5% | >999% | -95.2% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -91.8% | -0.8% | -92.6% | -0.1% | -92.9% | -2.1% | -91.4% | +5.9% | -92.0% | +3.8% | -92.2% | +19.8% | -92.3% | +22.0% | -90.8% | +20.1% | -92.0% | +23.2% | -92.2% | +10.9% | -93.2% | +9.4% | -92.4% | +9.4% | -93.7% | +12.4% | -93.7% | +8.6% | -95.1% | +5.8% | -95.0% |
Range$411M – $9.87B
CAGR-24.7%
Avg YoY Growth-41.7%
Median YoY Growth-46.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's xgeva — total revenues?
- Amgen (AMGN) reported xgeva — total revenues of $411M in Q1 2026.
- How has Amgen's xgeva — total revenues changed year-over-year?
- Amgen's xgeva — total revenues decreased by 95.0% year-over-year, from $8.15B to $411M.
- What does xgeva — total revenues mean?
- The total revenue generated from sales of the XGEVA therapeutic product.